Ligand Partner Seelos Therapeutics Becomes a Public Company

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics, Inc., is publicly traded on the Nasdaq Capital Market under the trading symbol ?SEEL,? and will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas wit